Top Botox Brands: Elevate Your Aesthetic Game

Botox injections have grown increasingly popular for their ability to reduce the appearance of fine lines and wrinkles, with a variety of brands available to cater to different needs and preferences. Some of these brands across the market include well-known names that are reputed for their effectiveness and safety. With various products offering unique formulations, it's essential to choose a brand that aligns with your specific aesthetic goals and medical requirements. To help you make an informed decision, we’ve compiled a list of some of the best brands for Botox injections below.

Illustration of botox injections

Best brands of botox injections in 2025

Allergan

Allergan, now part of AbbVie, is a leading and trusted producer of Botox injections, dominating over half of the global botulinum toxin A market. Approved for use in 98 countries, Allergan's Botox is the gold standard and most widely-researched botulinum toxin type A treatment, with its efficacy documented in over 528 peer-reviewed articles. In 2022, Allergan led the global botulinum toxin A market, and the product is expected to drive market growth with a CAGR of 6.5% until 2029. Botox is FDA-approved for treating various cosmetic and medical conditions, including frown lines, crow's feet, and forehead lines, as well as medical uses such as migraines and excessive sweating. The global botulinum toxin A market, led by Allergan, is projected to reach nearly $10.2 billion by 2029.

Ipsen

Ipsen, through its brand Dysport, is a leading producer of botulinum toxin type A, with a significant global presence in over 85 countries. Dysport has been approved for various therapeutic uses, including treating cervical dystonia, adult upper and lower limb spasticity, and pediatric cerebral palsy, and it also dominates the aesthetics market with strong demand for non-surgical procedures to diminish facial wrinkles. In 2023, Dysport contributed to Ipsen's robust sales growth, with a 14.5% increase in sales, highlighting its market impact. Ipsen holds the second largest share in the global botulinum toxin market, with Dysport driving much of this success. The product's long-term efficacy and lower yearly cost compared to Botox further enhance its market position.

Merz Pharmaceuticals

Merz Pharmaceuticals, through its brand Xeomin, is a significant player in the botulinum toxin A market, known for its highly purified, freeze-dried formulation of botulinum neurotoxin type A. Xeomin is approved for various indications, including cervical dystonia, blepharospasm, and glabellar frown lines, and it does not require refrigeration, simplifying distribution. It has been shown to be non-inferior to Botox in clinical trials and has a lower risk of developing antibodies due to the absence of complexing proteins. Xeomin is priced at a 20-40% discount relative to Botox, making it a competitive alternative. Since its approval, over 84,000 people worldwide have been treated with Xeomin injections.

Galderma

Galderma, a leading player in the global botulinum toxin market, holds a significant position with its flagship products such as Dysport and Azzalure, capturing a market share of 33% in 2021. The company's products are widely used for treating various types of wrinkles and other aesthetic procedures, with a strong presence in North America and Europe. Galderma achieved record net sales of $2.2 billion in the first half of 2024, reflecting a 10.8% year-on-year growth at constant currency, driven by volume growth and a favorable product mix. The company's Injectable Aesthetics category saw a notable 13.4% growth in the same period. Galderma's success is also marked by its broad-based growth across all product categories and geographies. For more information, visit Galderma's official website.

Hugel

Hugel, a leading global medical aesthetics company, is renowned for its high-quality botulinum toxin type A products, including Botulax (known as Letybo in the U.S.), which has been the market leader in South Korea for seven consecutive years. The company has sold over 26 million vials in more than 50 countries, including Australia, Canada, and Europe. Hugel's product has demonstrated efficacy and safety in treating glabellar lines through multiple phase III clinical trials involving over 1,000 subjects. The company achieved a 62% growth in overseas botulinum toxin sales year-on-year, driven by increased demand in China and Europe. With FDA approval in the U.S., Hugel is set to launch Letybo in the second half of 2024, aiming to secure a 10% share of the U.S. toxin market.

Medytox

Medytox, through its product Neuronox, has established itself as a significant player in the botulinum toxin market. Approved by the Korean Food and Drug Administration in 2006, Neuronox has been registered in 32 countries and has become the No.1 selling botulinum toxin product in Korea and Thailand. Clinical studies have shown that Neuronox is non-inferior to Botox in terms of efficacy and safety, with response rates of up to 93.8% in treating glabellar lines. Medytox has achieved a domestic market share of over 50% in Korea and has sold over 12 million vials of Neuronox worldwide. The company is also poised to expand its presence in the Chinese market, with a projected market growth rate of 15%. For further details, you can view the official report on Neuronox.

Daewoong Pharmaceutical

Daewoong Pharmaceutical has established itself as a leading producer of botulinum toxin products, particularly with its brand Nabota, known as Jeuveau in the US. Nabota has achieved significant growth, with a 93.3% year-over-year increase in revenue and securing a 12% market share in the US botulinum toxin market by 2023, just five years after its launch in the US. The product has also surpassed 600,000 customers in the US, with a 96% re-treatment rate, indicating high customer satisfaction. Daewoong's Hi-Pure Technology ensures the production of botulinum toxin with over 98% purity, contributing to its quality competitiveness. The company projects an annual growth rate of approximately 20% through 2030 for its botulinum toxin products. For more detailed information, visit the full article on Daewoong Pharmaceutical's market impact.

Revance Therapeutics

Revance Therapeutics is a leading biotechnology company that has revolutionized the field of neuromodulators with its innovative product, Daxxify (daxibotulinumtoxinA-lanm). Approved by the FDA in September 2022 for the temporary improvement of glabellar lines and in August 2023 for the treatment of cervical dystonia, Daxxify stands out due to its long-acting formulation stabilized by Peptide Exchange Technology™. This technology allows it to last longer than conventional neuromodulators. The product has shown significant potential, with a 50% increase in orders observed just a week after a price adjustment in September 2023. Daxxify is poised to capture a substantial share of the growing $8 billion neuromodulator market by 2025. Its differentiated duration and competitive pricing are expected to accelerate market expansion. For more details, visit the Revance Therapeutics press release.

Lanzhou Institute of Biological Products

The Lanzhou Institute of Biological Products is a prominent producer of botulinum toxin type A, with its product being one of the first two BTX products licensed in China. This toxin, known as BTXA or Chintox, has been approved since January 1, 1997, for various indications including blepharospasm, skin diseases, spasm, and strabismus. It operates as a SNAP25 inhibitor, effectively blocking muscle movement and reducing wrinkles and spasms. The institute's product has a long history of use and has undergone extensive clinical trials, including phase 3 studies for conditions like crow's feet and masticatory muscle hypertrophy. Its efficacy and safety have been well-documented, making it a trusted choice in the aesthetic and therapeutic markets. For further details, explore the comprehensive clinical trial data.

Evolus

Evolus, the company behind the Jeuveau brand, has emerged as a significant player in the cosmetic neurotoxin market, particularly with its rapid growth since Jeuveau's FDA approval in 2019. In 2021, Jeuveau saw a 76% increase in sales, reaching $99.7 million, driven by a successful marketing strategy targeting millennials and the medical spa sector. As of 2023, Jeuveau holds an 11% market share in the U.S. neurotoxin category, with Botox dominating at 70%. Jeuveau is positioned as a more affordable option, being 20-25% less expensive than Botox, and is known for its faster onset and longer-lasting effects. The company continues to expand, with a European launch and plans for further product development, aiming for $255 million to $265 million in revenue for 2024.